← Back to guidelines
Ophthalmology12 papers

Juvenile neuronal ceroid lipofuscinosis

Last edited: 4/16/2026

Overview

Juvenile neuronal ceroid lipofuscinosis (JNCL, Batten disease) is an autosomal recessive lysosomal storage disorder characterized by the accumulation of ceroid-lipofuscin, leading to progressive neurological deterioration including vision loss, seizures, and motor dysfunction, typically resulting in premature death around age 30 1.

Diagnosis

  • Clinical Presentation: Loss of vision in childhood, followed by seizures, motor dysfunction, and cognitive decline 1.
  • Genetic Testing: Essential for confirmation; common mutation is a 1.02 kb deletion in CLN3 gene, but novel mutations like c.597C>A (p.Y199X) can also cause the disease 1.
  • Electron Microscopy: Lymphocytes showing fingerprint profiles indicative of JNCL 1.
  • Family History: Important, especially in consanguineous families where disease clustering may occur 1.
  • Management

  • No Cure Available: Current management focuses on supportive care and symptom control 1.
  • Seizure Control: Antiepileptic drugs tailored to seizure types (e.g., valproate, levetiracetam) 1.
  • Motor and Cognitive Support: Physical and occupational therapy to maintain function 1.
  • Vision Aids: Low-vision aids and regular ophthalmological follow-up 1.
  • Nutritional Support: Ensuring adequate nutrition and addressing feeding difficulties 1.
  • Psychosocial Support: Multidisciplinary approach including psychological support for patients and families 1.
  • Special Populations

  • Pediatrics: Early diagnosis and intervention crucial for managing symptoms and improving quality of life 1.
  • Comorbidities: Management of comorbidities like epilepsy requires individualized treatment plans 1.
  • Key Recommendations

  • Genetic Testing for Diagnosis: Confirm diagnosis through genetic testing, including screening for novel CLN3 mutations (Evidence: Moderate 1).
  • Multidisciplinary Care Approach: Implement a comprehensive care plan involving neurology, ophthalmology, physical therapy, and psychosocial support (Evidence: Expert opinion 1).
  • Seizure Management: Tailor antiepileptic drug therapy based on seizure types and clinical response (Evidence: Moderate 1).
  • References

    1 Sarpong A, Schottmann G, Rüther K, Stoltenburg G, Kohlschütter A, Hübner C et al.. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X). Clinical genetics 2009. link

    Original source

    1. [1]
      Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X).Sarpong A, Schottmann G, Rüther K, Stoltenburg G, Kohlschütter A, Hübner C et al. Clinical genetics (2009)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG